首页> 美国卫生研究院文献>Gut >Actions of the 5-hydroxytryptamine 1 receptor agonist sumatriptanon interdigestive gastrointestinal motility in man
【2h】

Actions of the 5-hydroxytryptamine 1 receptor agonist sumatriptanon interdigestive gastrointestinal motility in man

机译:5-羟色胺1受体激动剂舒马曲坦的作用消化系统胃肠动力的研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background—Pharmacological studies of the enteric nervous system have shown the presence of several subtypes of 5-hydroxytryptamine (5HT) receptor, which might be involved in control of the migrating motor complex.
Aims—To study the effect of sumatriptan, an agonist of enteric neuronal 5HT1P receptors, on interdigestive motility in man.
Subjects and methods—In 12 healthy subjects, interdigestive motility was recorded manometrically in the upper gastrointestinal tract. In seven subjects blood samples were drawn every 15 minutes for radioimmunoassay of motilin and somatostatin. After two phase 3s of the migrating motor complex, 6 mg of sumatriptan was administered subcutaneously. Recording continued until two more phase 3s had occurred.
Results—Sumatriptan induced a premature phase 3 in the jejunum after a median of 10 (8) minutes. The duration of the migrating motor complex cycle was shortened at the expense of phase 2. After sumatriptan, plasma somatostatin concentrations were reduced and gastric phase 3s were suppressed, although median motilin concentrations and the occurrence of plasma motilin peaks were not affected. Phase 3s of the migrating motor complex preceding sumatriptan were associated with motilin peaks, while phase 3s after sumatriptan were not. Furthermore, pretreatment with sumatriptan prevented the induction of a gastric phase 3 by the motilin agonist erythromycin.
Conclusions—Administration of the 5HT1P receptor agonist sumatriptan induces a prematureintestinal phase 3, suppresses gastric phase 3s, prevents induct-ion of a gastric phase 3 by erythromycin, and reduces plasmasomatostatin concentrations.

Keywords:migrating motor complex; motilin; somatostatin; erythromycin; enteric nervous system
机译:背景—肠道神经系统的药理研究表明,存在5-羟色胺(5HT)受体的几种亚型,这些亚型可能与迁移运动复合体的控制有关。
目标-研究舒马曲坦(肠神经元5HT1P受体激动剂)对人消化系统运动的影响。
受试者和方法-在12名健康受试者中,消化道蠕动被测压记录在上消化道中。在七个受试者中,每隔15分钟抽取一次血液样本进行胃动素和生长抑素的放射免疫分析。在两个阶段的迁移运动复合物3s后,皮下注射舒马普坦6 mg。继续记录直到发生另外两个阶段3。
结果-舒马曲坦中位数10(8)分钟后,在空肠中诱导了过早的3期。尽管不影响中值胃动素浓度和血浆胃动素峰的发生,但以阶段2为代价缩短了迁移运动复合体周期的持续时间,但减少了阶段2的舒马曲坦后血浆血浆生长抑素浓度并抑制了胃3s阶段。舒马曲坦之前的迁移运动复合物的3s阶段与胃动素峰相关,而舒马曲坦之后的3s阶段与运动相关。此外,舒马曲坦的预处理可防止胃动素激动剂红霉素诱导胃相3的发生。
结论-5HT1P受体激动剂舒马曲坦的给药引起早产肠道3期,抑制胃3s,防止诱导-霉素对胃3的离子化,降低血浆生长抑素浓度。

关键字:迁移运动综合体;胃动素生长抑素红霉素肠神经系统

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号